SciELO - Scientific Electronic Library Online

 
vol.33 issue3Turbid acellular peritoneal fluid and the use of calcium antagonists in peritoneal dialysisMagnesium - its role in CKD author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Share


Nefrología (Madrid)

On-line version ISSN 1989-2284Print version ISSN 0211-6995

Abstract

LOPEZ-HOYOS, Marcos; RODRIGO, Emilio  and  ARIAS, Manuel. The usefulness of intracellular adenosine-5'-triphosphate measurement in CD4+ cells in renal transplant. Nefrología (Madr.) [online]. 2013, vol.33, n.3, pp.381-388. ISSN 1989-2284.  https://dx.doi.org/10.3265/Nefrologia.pre2012.Oct.11540.

ImmuKnow® is an in vitro diagnosis method that uses patient samples of whole blood polyclonally stimulated with phytohaemagglutinin. It also measures adenosine-5'-triphosphate (ATP) production by CD4+ T cells. The test aims to offer an objective and overall measurement of each individual's cellular immune response. The assay was designed with the idea of individually monitoring the immunosuppression administered to transplant patients. At the same time, it aims to help achieve a balance as a way of avoiding immunosuppression excess and the associated adverse effects (infections, cancer, etc.) or an immunosuppression defect and the subsequent risk of allograft rejection. The majority of studies that have evaluated its clinical usefulness display great diversity in terms of patient recruitment, the immunosuppressant treatment received, the clinical variables analysed and, above all, the time between performing ImmuKnow® and the evaluated clinical event. The most consistent data show that this assay on CD4+ T cell functioning is useful for predicting the risk of infection in renal transplant patients. However, its use as a rejection risk indicator is unclear. Lastly, given the great variability of immune response amongst individuals and that of existing publications, it can be deduced that the isolated ImmuKnow® value does not have diagnostic capacity and only individual serial monitoring could provide definitive assistance in clinical decision making and immunosuppressant treatment changes. Other aspects of ImmuKnow® application in the clinical routine, such as assay cycles, require randomised prospective studies for more comprehensive information.

Keywords : Renal transplantation; Patient survival; Inmunosuppression; Comorbidity; Mortality.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License